Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:PKI

Revvity (PKI) Stock Price, News & Analysis

Revvity logo

About Revvity Stock (NYSE:PKI)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$115.24
$137.11
52-Week Range
N/A
Volume
1.63 million shs
Average Volume
851,117 shs
Market Capitalization
$14.57 billion
P/E Ratio
15.01
Dividend Yield
0.24%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Revvity, Inc provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics.? The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.

Receive PKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revvity and its competitors with MarketBeat's FREE daily newsletter.

PKI Stock News Headlines

Revvity, Inc. (RVTY)
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
Revvity Inc PKI
See More Headlines

PKI Stock Analysis - Frequently Asked Questions

Revvity, Inc. (NYSE:PKI) posted its quarterly earnings data on Thursday, May, 11th. The medical research company reported $1.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.07 by $0.06. The medical research company had revenue of $674.87 million for the quarter, compared to analyst estimates of $686.30 million. Revvity had a trailing twelve-month return on equity of 11.17% and a net margin of 28.94%.

Revvity's Board of Directors initiated a stock buyback program on Thursday, May 11th 2023, which permits the company to repurchase $600,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 4.1% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's leadership believes its shares are undervalued.

Revvity subsidiaries include these companies: BioLegend, Immunodiagnostic Systems, Nexcelom Bioscience, SIRION Biotech, Oxford Immunotec, Horizon Discovery, Cisbio.com, and others.

Based on aggregate information from My MarketBeat watchlists, some other companies that Revvity investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), Visa (V), Home Depot (HD) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
5/11/2023
Today
5/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NYSE:PKI
Employees
16,700
Year Founded
1937

Profitability

Trailing P/E Ratio
15.01
Forward P/E Ratio
N/A
P/E Growth
0.5
Net Income
$569.18 million
Pretax Margin
13.81%

Debt

Sales & Book Value

Annual Sales
$3.31 billion
Price / Cash Flow
9.88
Book Value
$58.49 per share
Price / Book
N/A

Miscellaneous

Free Float
125,755,000
Market Cap
$14.57 billion
Optionable
Optionable
Beta
1.10

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NYSE:PKI) was last updated on 5/8/2025 by MarketBeat.com Staff
From Our Partners